Contamination Control in Nursing with Filtration. Part 2: Emerging Rationale for Bedside (Final) Filtration of Prestorage Leukocyte-reduced Blood Products

Journal of Infusion Nursing

Volumn 27, Issue 3, 2004, Pages 157-165

  Ortolano, Girolamo A ^a   Russell, Rosalind L ^a   Angelbeck, Judy A ^a   Schaffer, Jeffrey ^a   Wenz, Barry ^b  

^a PALL CORPORATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ANTIGEN;

ALLOIMMUNIZATION; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CONTAMINATION; CONTROL SYSTEM; CYTOMEGALOVIRUS; FILTRATION; HOSPITAL CARE; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; MEDIATOR RELEASE; NURSING; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; REVIEW; RISK BENEFIT ANALYSIS;

BLOOD COMPONENT TRANSFUSION; FILTRATION; HUMANS; LEUKOCYTES; NURSING STAFF, HOSPITAL; POINT-OF-CARE SYSTEMS;

EID: 2342519505     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200405000-00004     Document Type: Review

References (35)

1. Harris DJ. Immune complications associated with chronic transfusion. J Infus Nurs. 2002;25:316-319.
2. Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion. 2001;41:691-712.
3. Wortham ST, Ortolano GA, Wenz W: A brief history of blood filtration: clot screens, microaggregate removal, and leukocyte reduction. Transfus Med Rev. 2003;17(3):216-222.
4. Otto SE, Understanding the immune system: overview for infusion assessment. J Infus Nurs. 2003;26:79-85.
5. Ortolano GA, Russell R, Capetandes A, Wenz B. Transfusion-associated immunosuppression: heuristic model or clinical concern. Mod Aspects Immunobiol. 2002;2(4):159-165.
6. Clancy J, Morgan J, Clancy Jr J, eds. Basic Concepts in Immunology: A Student's Survival Guide. McGraw-Hill; 1997:223.
7. Schreuder GM, Hurley CK, Marsh SG, et al. The HLA Dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. Tissue Antigens. 2001;58:109-140.
8. Fiebig E, Lane TA. Effect of storage and ultraviolet B irradiation on CD14-bearing antigen-presenting cells (monocytes) in platelet concentrates. Transfusion. 1994;34:846-851.
9. Mincheff MS, Meryman HT. Blood transfusion, blood storage, and immunomodulation. Immunol Invest. 1995;24:303-309.
10. Fast LD. Recipient elimination of allogeneic lymphoid cells: donor CD4(+) cells are effective alloantigen-presenting cells. Blood. 2000;96:1144-1149.
11. Claas FH, Roelen DL, van Rood JJ, Brand A. Modulation of the alloimmune response by blood transfusions. Transfus Clin Biol. 2001;8:315-317.
12. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337:1861-1870.
13. Nickerson P, Pochinco D, Dembinski I, et al. Effect of universal leukocyte reduction of packed RBC transfusions on allosensitization in a dialysis population. Human Immunol. 2002;60(Suppl 10): S81. Abstract 89.
14. Tegtmeier GE. Cytomegalovirus infection as a complication of blood transfusion. Semin Liver Dis. 1986;6:82-95.
15. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86(9):3598-3603.
16. Kothari A, Ramachandran VG, Gupta P, Singh B, Talwar V. Sero-prevalence of cytomegalovirus among voluntary blood donors in Delhi, India. J Health Popul Nutr. 2002;20:348-351.
17. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leuko-reduced blood products. Blood. 2003;101:4195-4200.
18. Perkins HA, Payne R, Ferguson J, Wood M. Nonhemolytic febrile transfusion reactions: quantitative effects of blood components with emphasis on isoantigenic incompatibility of leukocytes. Vox Sang. 1966;11:578-600.
19. Andreu G, Morel P, Forestier F, et al. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion. 2002;42:1356-1364.
20. Heddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion. 1999;39:231-238.
21. Killick SB, Win N, Marsh JC, et al. Pilot study of HLA alloimmunization after transfusion with prestorage leucodepleted blood products in aplastic anaemia. Br J Haematol. 1997;97:677-684.
22. Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Transfusion, 1993;33:195-199.
23. Ibojie J, Greiss MA, Urbaniak SJ. Limited efficacy of universal leucodepletion in reducing the incidence of febrile nonhaemolytic reactions in red cell transfusions. Transfus Med. 2002;12:181-185.
24. Snyder EL, Mechanic S, Baril L, Davenport R. Removal of soluble biologic response modifiers (complement and chemokines) by a bedside white cell-reduction filter. Transfusion. 1996;36:707-713.
25. Geiger TL, Perrotta PL, Davenport R, Baril L, Snyder EL. Removal of anaphylatoxins C3a and C5a and chemokines interleukin 8 and RANTES by polyester white cell-reduction and plasma filters. Transfusion. 1997;37:1156-1162.
26. Opelz G, Sengar DP, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc. 1973;5:253-259.
27. Opelz G, Vanrenterghem Y, Kirste G, et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation. 1997;63:964-967.
28. Blajchman MA, Dzik S, Vamvakas EC, Sweeney J, Snyder EL. Clinical and molecular basis of transfusion-induced immunomodulation: summary of the proceedings of a state-of-the-art conference. Transfus Med Rev. 2001;15:108-135.
29. Wenz B, Ortolano GA. Leukocyte reduction and HTLV-I: is the glass half empty or half full? Blood. 2003;101:370.
30. Mynster T, Nielsen HJ. The impact of storage time of transfused blood on postoperative infectious complications in rectal cancer surgery. Danish RANX05 Colorectal Cancer Study Group. Scand J Gastroenterol. 2000;35:212-217.
31. Offner PJ, Moore EE, Biffl WL, Johnson JL, Silliman CC. Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg. 2002;137:711-716.
32. Ghio M, Contini P, Mazzei C, et al. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood. 1999;93:1770-1777.
33. Wenz B, Ortolano GA. Effect of universal WBC reduction. Transfusion. 2003;43(6):831-833.
34. Prins HA, Houdijk AP, Nijveldt RJ, et al. Arginase release from red blood cells: possible link in transfusion-induced immune suppression? Shock. 2001;16:113-115.
35. Ortolano GA, Angelbeck JA, Russell R, Capetandes A, Wenz B. A Commentary and Perspective on the Status of Universal Leukocyte Reduction. East Hills, NY: Pall Corporation; 2003:1-27. Reorder code ULRpaper2003 at http://www.pall.com/applicat/medical/pdf/ULRPaper2003.pdf